SuperworthNephros EPS NEPH
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.16
- Latest quarter, Q2 FY26
- $0.11
- +450% on a year earlier
- Fiscal year 2025
- $0.11
Nephros' earnings per share was $0.16 over the twelve months to Jun 30, 2026, up 33% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.11, up 450% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.11 | n/a |
| FY2024 | $0.00 | n/a |
| FY2023 | −$0.15 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$0.41 | n/a |
| FY2020 | −$0.52 | n/a |
| FY2019 | −$0.47 | n/a |
| FY2018 | −$0.55 | n/a |
| FY2017 | −$0.09 | n/a |
| FY2016 | −$0.54 | n/a |
| FY2015 | −$1.08 | n/a |
| FY2014 | −$4.23 | n/a |
| FY2013 | −$2.25 | n/a |
| FY2012 | −$2.52 | n/a |
| FY2011 | −$3.06 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.11 | +450% | $0.16 | |
| Q1 FY26 | $0.01 | −80% | $0.07 | |
| Q4 FY25 | $0.01 | −67% | $0.11 | |
| Q3 FY25 | $0.03 | +50% | $0.13 | |
| Q2 FY25 | $0.02 | n/a | $0.12 | |
| Q1 FY25 | $0.05 | n/a | $0.07 | |
| Q4 FY24 | $0.03 | n/a | $0.00 | |
| Q3 FY24 | $0.02 | n/a | −$0.09 | |
| Q2 FY24 | −$0.03 | n/a | −$0.13 | |
| Q1 FY24 | −$0.02 | n/a | −$0.14 | |
| Q4 FY23 | −$0.06 | n/a | −$0.15 | |
| Q3 FY23 | −$0.02 | n/a | −$0.18 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| Peer median | $2.12 |
Where Nephros ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Nephros
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.